Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
omega-3 fatty acids (Shahid Beheshti University of Medical Sciences)
- Development stage
- Phase 1
- Lead developer
- Shahid Beheshti University of Medical Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Omega-3 fatty acids, primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are being investigated by Shahid Beheshti University of Medical Sciences in a Phase 3 clinical trial (NCT01521845) for their potential to reduce periprocedural myocardial injury in patients with coronary arteriosclerosis undergoing elective percutaneous coronary intervention (PCI). The treatment aims to lower biomarkers of cardiac necrosis, such as CK-MB and Troponin I, and inflammatory markers like C-reactive protein (CRP). Mechanistically, these polyunsaturated fatty acids incorporate into cell membranes and modulate inflammatory pathways by competing with arachidonic acid for enzymatic conversion into pro-inflammatory mediators, thereby exerting cardioprotective and anti-inflammatory effects.
- Other names
- EPADHAeicosapentaenoic aciddocosahexaenoic acidn-3 polyunsaturated fatty acidsn3 polyunsaturated fatty acidsn 3 polyunsaturated fatty acidsn-3 PUFAn3 PUFAn 3 PUFA
02
Targets
FFAR4 (Free fatty acid receptor 4)PPARA (Peroxisome proliferator-activated receptor alpha)PPARG (Peroxisome proliferator-activated receptor gamma)ALOX5 (Arachidonate 5-lipoxygenase)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)
Beyond the preview
Go deeper on omega-3 fatty acids (Shahid Beheshti University of Medical Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on omega-3 fatty acids (Shahid Beheshti University of Medical Sciences).